Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Nicole, Brighi"'
Autor:
Chiara Casadei, Emanuela Scarpi, Vincenza Conteduca, Giorgia Gurioli, Maria Concetta Cursano, Nicole Brighi, Cristian Lolli, Giuseppe Schepisi, Umberto Basso, Giuseppe Fornarini, Sara Bleve, Alberto Farolfi, Amelia Altavilla, Salvatore Luca Burgio, Emilio Francesco Giunta, Caterina Gianni, Alessia Filograna, Paola Ulivi, David Olmos, Elena Castro, Ugo De Giorgi
Publikováno v:
European Urology Open Science, Vol 61, Iss , Pp 44-51 (2024)
Background: The prevalence of pathogenic germline mutations in DNA damage repair (gDDR) genes in the Italian population is unknown. Objective: In this prospective multicenter cohort study, we evaluated the prevalence of gDDR alterations in the Italia
Externí odkaz:
https://doaj.org/article/da61ee9b940b4381ac3aa92030e5b551
Autor:
Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 1381-1394 (2023)
Temozolomide (TEM) as a single agent or in combination with capecitabine (CAPTEM) is active in well-differentiated advanced neuroendocrine tumors (NETs) of gastro-entero-pancreatic and thoracic origin. The predictive role of MGMT-promoter methylation
Externí odkaz:
https://doaj.org/article/cf7e4e02ab344cf889febb7e58d3a49a
Autor:
Chiara Tommasi, Giulia Scartabellati, Diana Giannarelli, Ugo De Giorgi, Nicole Brighi, Giuseppe Fornarini, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Matteo Brunelli, Sebastiano Buti
Publikováno v:
Therapeutic Advances in Urology, Vol 15 (2023)
Background: Tyrosine-kinase inhibitors (TKIs) and immunotherapy represent the backbone treatment for metastatic renal cell carcinoma (mRCC) patients. The aim of the present study was to describe mean corpuscular volume (MCV) and red cell distribution
Externí odkaz:
https://doaj.org/article/2c36da92decd496ba6b3b43f3902e571
Autor:
Vincenza Conteduca, Emanuela Scarpi, Paola Caroli, Cristian Lolli, Giorgia Gurioli, Nicole Brighi, Giulia Poti, Alberto Farolfi, Amelia Altavilla, Giuseppe Schepisi, Federica Matteucci, Giovanni Paganelli, Ugo De Giorgi
Publikováno v:
Molecular Oncology, Vol 16, Iss 2, Pp 538-548 (2022)
Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC
Externí odkaz:
https://doaj.org/article/5d48a31c73474ecbbe4e84ec246466a7
Autor:
Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, Emanuela Scarpi, Umberto Basso, Giuseppe Fornarini, Alessandra Mosca, Maurizio Nicodemo, Giuseppe Luigi Banna, Cristian Lolli, Giuseppe Schepisi, Giorgia Ravaglia, Isabella Bondi, Paola Ulivi, Ugo De Giorgi
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background Cabazitaxel improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we evaluated the prognostic role of CTC gene expression on caba
Externí odkaz:
https://doaj.org/article/d29eb01c551a427fb416b8fbeaed9d19
Autor:
Maria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, Chiara Casadei, Alessandra Virga, Paola Ulivi, Sara Bleve, Nicole Brighi, Giorgia Ravaglia, Francesco Pantano, Vincenza Conteduca, Daniele Santini, Ugo De Giorgi
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 15, p 12436 (2023)
Up to 80% of castration-resistant prostate cancer (CRPC) patients develop bone metastases during the natural history of disease and about 25% harbor mutations in DNA damage repair (DDR) genes. This retrospective observational study evaluated the prev
Externí odkaz:
https://doaj.org/article/aea86f181b884388b59e91f18d738bb7
Autor:
Giulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, Francesca Trentini, Ugo De Giorgi, Nicole Brighi, Chiara Tommasi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Enrico Maria Silini, Pasquale Rescigno, Sara Elena Rebuzzi, Giuseppe Fornarini, Federico Quaini, Giulia Claire Giudice, Giuseppe Luigi Banna, Sebastiano Buti
Publikováno v:
Frontiers in Bioscience-Elite, Vol 15, Iss 3, p 20 (2023)
Background: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the metastatic renal cell carcinoma (mRCC) therapeutic landscape. Nevertheless, tyrosine-kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF)
Externí odkaz:
https://doaj.org/article/922e18e923f6408ebcb291c324656551
Autor:
Giandomenico Roviello, Martina Catalano, Ugo De Giorgi, Marco Maruzzo, Sebastiano Buti, Elisabetta Gambale, Giuseppe Procopio, Carlotta Ottanelli, Enrico Caliman, Luca Isella, Pierangela Sepe, Nicole Brighi, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAlthough serum sodium concentration, particularly hyponatremia, has been shown to be a prognostic marker of survival in metastatic renal cell carcinoma (mRCC), the impact of normal sodium levels has not been investigated. Herein, we investi
Externí odkaz:
https://doaj.org/article/c05b7b7444424caf8d07cb9291a2892b
Autor:
Vincenza Conteduca, Emanuela Scarpi, Alberto Farolfi, Nicole Brighi, Lorena Rossi, Giorgia Gurioli, Cristian Lolli, Giuseppe Schepisi, Sara Bleve, Caterina Gianni, Alessandra Virga, Amelia Altavilla, Salvatore Luca Burgio, Cecilia Menna, Ugo De Giorgi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionMelphalan, as a bifunctional alkylating agent has been shown to be selectively efficient in BRCA-deficient case reports of epithelial ovarian cancer (EOC). The clinical benefit of melphalan on unselected platinum-resistant EOC population
Externí odkaz:
https://doaj.org/article/0d813f666bc6489d8c6434d5622e0e9c
Autor:
Vincenza Conteduca, Giulia Poti, Paola Caroli, Sabino Russi, Nicole Brighi, Cristian Lolli, Giuseppe Schepisi, Antonino Romeo, Federica Matteucci, Giovanni Paganelli, Paolo Marchetti, Ugo De Giorgi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Over the years, an increasing proportion of metastatic prostate cancer patients has been found to experience an initial bone flare phenomenon under both standard therapies (androgen deprivation therapy, chemotherapy, radiotherapy, abiraterone, enzalu
Externí odkaz:
https://doaj.org/article/6358497e9f7348b1ba7829da89a45252